We report a pediatric case of CAEBV and T cell-based Hodgkin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling. The diagnosis of CAEBV was made from clinical signs and the presence of the EBV genome in PBMC and tumor cells. Conditioning with busulfan (BU) ؉ etoposide (VP16) ؉ cyclophosphamide (CY) was effective and well tolerated. EBV was totally eradicated by 3 months after allo PBSCT. Although she suffered from chronic GVHD of the liver, she has been well and free of disease for 47 months since PBSCT. We suggest allo PBSCT for CAEBV as a potent therapeutic strategy for eradication of the EBV genome and allowing immunological reconstitution.
CAEBV is an on-going EBV infection characterized by repeated infectious mononucleosis(IM)-like symptoms and a very high titer of anti-EBV antibodies and a low titer of EBNA. 1 It is believed that CAEBV is caused by deficiency of EBV-specific immune response; however, the true mechanism remains unknown. It is often associated with lymphoid malignancies and the EBV genome is frequently detected in tumor cells. Although there are several reports of CAEBV therapy with anti-viral agents, cytokines or immunotherapy, [2] [3] [4] [5] they only allow temporary resolution. The ultimate prognosis of CAEBV is very poor and to date there are no established treatment strategies for this disorder. We report a case of CAEBV and T cell-based Hodg- kin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling.
Case report
A 9-year-old girl was admitted to a regional hospital with fever and lymph node swelling. She was diagnosed with malignant lymphoma on lymph node biopsy ( Figure 1 ) and admitted to our hospital in April 1997. She had had a primary EBV infection when she was 8 years old and suffered from recurrent tonsillitis. She was allergic to mosquito bites. On examination, hepatosplenomegaly was noted. No skin lesions were observed. A bilateral mediastinal mass was noted on chest X-ray. On blood examination, hyperimmunoglobulinemia was noted. The titers of anti-EBV antibodies were as follows: VCA-IgG ϫ 5120, EADR-IgG ϫ 10 240 and EBNA ϫ 20. Cell surface marker analysis showed that the CD4/8 ratio of PBMC was 0.34 and most of the cells were positive for CD3, 8, 57 and TCR ␣/␤. The mitogen responses were decreased and natural killer (NK) cell activity was low. EBV genome DNA was detected by PCR in PBMC and EBV related RNA by in situ hybridization (ISH) in CD8-positive PBMC separated by immuno-magnetic beads method and lymph node cells ( Figure 2 ). The diagnosis of CAEBV was made based on the very high titer of anti-EBV antibodies and the presence of the EBV genome in the PBMC and lymph node cells on PCR and ISH. She was initially treated with prednisolone (PSL) 60 mg/m 2 for 4 weeks, and vincristine (VCR) 1.5 mg/m 2 weekly administered five times. With this therapy, the mediastinal mass decreased markedly, but she developed a high fever and marked splenomegaly only 2 weeks after cessation of the therapy. Two more courses of chemotherapy including high-dose methyl PSL (20 mg/kg/day for 3 days), cytarabine and CY were then tried. However, the high fever was controlled only by steroid therapy and splenomegaly was observed throughout the clinical course while she was receiving chemotherapy. Although anti-EBV VCA IgG and EADR-IgG were slightly decreased, the EBV genome remained positive in PBMC throughout her clinical course. The patient had an HLAmatched brother, and allo PBSCT was planned. For PBSC mobilization, G-CSF (10 g/kg) was used for 5 days. Allo PBSCT was performed following conditioning with BU 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg), VP16 40 mg/kg once and CY 60 mg/kg, once daily by i.v. for 2 days (total dose 120 mg/kg) in December 1997 ( Figure 3 ). Short-term methotrexate (sMTX) and cyclosporin A (CyA) were used for GVHD prophylaxis. Engraftment was observed 21 days after PBSCT. Although she developed veno-occlusive disease (VOD) of the liver 26 days after PBSCT, it was successfully treated by PSL. After PBSCT, the number of EBV-bearing CD8-positive cells and the titer of anti-EBV antibodies had decreased. Furthermore, an increase in mitogen response and NK cell activity was observed and her physical condition improved. The EBV genome in her PBMC disappeared by 3 months after PBSCT on both PCR and ISH. With later quantitative analysis by real-time PCR using BALF 5 region, 6 the EBV genome DNA in PBMC before PBSCT reached up to 319 747 copies/g DNA. However, it decreased to less than 20 copies/g DNA on day 100 post PBSCT. After the EBV had been eradicated, the mediastinal mass, high fever and splenomegaly also resolved. Although she suffered from shocked lung of unknown origin and chronic GVHD (cGVHD) of the liver, immunosuppressive therapy was discontinued 12 months after PBSCT and she has been well and free of disease for 47 months after PBSCT with no special treatment.
Discussion
EBV is associated with a number of hematological and nonhematological disorders. Of these disorders, CAEBV is summarized by Rickinson 1 in 1986 as a chronic, symptomatic EBV infection. Its clinical features are as follows: (1) chronic or recurrent IM-like symptoms lasting for a period of at least 1 year and often longer; (2) an unusual pattern of anti-EBV antibodies with increased anti-EA and/or absent anti-EBNA titer; and (3) no evidence of any prior immunological abnormality or of any other recent infection. We encountered a 9-year-old girl with malignant lymphoma and very high titers of anti-EBV VCA-IgG and EADR-IgG, and a low titer of EBNA. The EBV genome was detected in her PBMC and tumor cells by PCR and ISH. The clinical signs of CAEBV were a history of frequent tonsillitis IM-like symptoms, allergy to mosquito bites, splenomegaly and a mediastinal mass. According to the classification of EBV-associated T cell lymphoma proposed by Su et al, 7 our case was compatible with a nodebased T immunoblastic lymphoma including Hodgkin'slike lymphoma. At first, we treated her with steroids and combination chemotherapy. However, the effect was only transient. To date, there are several reports on CAEBV therapy with anti-viral agents, cytokines or immunotherapy, [2] [3] [4] [5] which only produce transient resolution and no established therapy is available. She had an HLA-matched brother and he had a normal anti-EBV titer indicating past infection, which suggested that he had cytotoxic T lymphocyte (CTL) activity for EBV. Finally, we performed an allogeneic stem cell transplant (SCT) to eliminate the EBV and allow immunological reconstitution. We selected PBSCT rather than BMT to ensure a larger dose of lymphocytes including EBV-specific CTLs and to ensure rapid immunological and hematological recovery. With PBSCT, adoptive immune transfer can be achieved from the donor with a normal immune response to EBV. 5 To date, there have been several reports of SCT for EBV-related hematological malignancies. [8] [9] [10] In these reports, the main purpose of SCT is the treatment of chemotherapy-resistant disease with megatherapy and to obtain an allogeneic immune response. In our case, the EBV-related lymphoproliferative disease was mild; however, the chronic active EBV infection itself was a serious problem. Thus, we decided to perform allo PBSCT in order to eradicate the EBV.
Preconditioning with BUϩVP16ϩCY was effective and well tolerated. Engraftment occurred 21 days after PBSCT. With immunological reconstitution, the number of EBVbearing CD8-positive cells and the titer of anti-EBV antibodies decreased. Furthermore, an increase in mitogen responses and NK cell activity was observed. The EBV genome in the PBMC disappeared by 3 months after PBSCT on both PCR and ISH. Although the patient suffered from VOD and GVHD of the liver, and shocked lung, these were successfully treated with no sequelae. She has been well and free of disease for 47 months since PBSCT. We emphasize the importance of allo PBSCT in the early stages of CAEBV. In the late stages of CAEBV, various organ dysfunctions occur and under these conditions, allogeneic SCT would be very risky with an increase in transplantation-related mortality. Fortunately, we were able to perform allo PBSCT for this patient while she had no organ dysfunction, which is likely to be the major reason for the successful outcome.
In conclusion, we suggest that allo PBSCT is an effective and safe alternative treatment for refractory CAEBV, partiBone Marrow Transplantation cularly when EBV actively infects the T cells. Recently, Fujii et al 11 described an allo PBSCT for CAEBV in an adult. Unfortunately, the patient died shortly afterwards although the EBV genome was shown to have been eradicated by the allo PBSCT. Further investigation and accumulation of case reports is needed to clarify the role of allo PBSCT for CAEBV.
